Methods and compositions for treatment of mydriasis
US12201615B2 · kind B2 · utility
0Cited by
74References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2022 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | Jul 29, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.